The single-nucleotide polymorphisms in CHD5 affect the prognosis of patients with hepatocellular carcinoma

Previous studies showed that the low expressions of chromodomain-helicase-DNA-binding protein 5 (CHD5) were intensively associated with deteriorative biologic and clinical characteristics as well as outcomes in many tumors. The aim of this study is to determine whether single nucleotide polymorphism...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2018-03, Vol.9 (17), p.13222-13230
Hauptverfasser: Zhu, Xiao, Kong, Qingming, Xie, Liwei, Chen, Zhihong, Li, Hongmei, Zhu, Zhu, Huang, Yongmei, Lan, Feifei, Luo, Haiqing, Zhan, Jingting, Ding, Hongrong, Lei, Jinli, Xiao, Qin, Fu, Weiming, Fan, Wenguo, Zhang, Jinfang, Luo, Hui
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Previous studies showed that the low expressions of chromodomain-helicase-DNA-binding protein 5 (CHD5) were intensively associated with deteriorative biologic and clinical characteristics as well as outcomes in many tumors. The aim of this study is to determine whether single nucleotide polymorphisms (SNPs) contribute to the prognosis of hepatocellular carcima (HCC). The SNPs were selected according to their linkage disequilibrium (LD) in the targeted next-generation sequencing (NGS) and then genotyped with TaqMan probers. We revealed a rare haplotype AG in (SNPs: rs12564469-rs9434711) was markedly associated with HCC prognosis. The univariate and multivariate regression analyses revealed the patients with worse overall survival time were those with tumor metastasis and haplotype AG, as well as cirrhosis, poor differentiation and IV-TNM stage. Based on the available public databases, we discovered the significant association between haplotype AG and mRNA expressions only existed in Chinese. These data proposed that the potentially genetic haplotype might functionally contribute to HCC prognosis and mRNA expressions.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.23812